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Temporal Trends in Incidence, Prevalence, and Mortality of Atrial
Fibrillation in Primary Care
Deirdre A. Lane, PhD;* Flemming Skjøth, PhD;* Gregory Y. H. Lip, MD;† Torben B. Larsen, MD, PhD; Dipak Kotecha, PhD;†
Background-—Incidence and prevalence of atrial ﬁbrillation (AF) are expected to increase dramatically; however, we currently lack
comprehensive data on temporal trends in unselected clinical populations.
Methods and Results-—Analysis of the UK Clinical Practice Research Datalink (CPRD) from 1998 to 2010 of patients with incident
AF, excluding major valvular disease, linked to hospital admission data and national statistics. Fifty-seven thousand eight hundred
eighteen adults were identiﬁed with mean age 74.2 (SD, 11.7) years and 48.3% women. Overall age-adjusted incidence of AF per
1000 person years was 1.11 (95% CI, 1.09–1.13) in 1998–2001, 1.33 (1.31–1.34) in 2002–2006, and 1.33 (1.31–1.35) in 2007–
2010. Ongoing increases in incidence were noted for patients aged ≥75 years, with similar temporal patterns in women and men.
Associated comorbidities varied over time, with a constant prevalence of previous stroke, increases in hypertension and diabetes
mellitus, and decreases in ischemic heart disease. Among patients aged 55 to 74 years, there was a signiﬁcant reduction in
mortality over time (P<0.001), but mortality rates in patients aged ≥75 years remained static at 14% to 15% per year (P=0.84).
Projections of AF prevalence demonstrated a constant yearly rise, increasing from 700 000 patients in 2010 to between 1.3 and
1.8 million patients with AF in the United Kingdom by 2060.
Conclusions-—In a large general practice population, incident AF increased and then plateaued overall, with a continued increase in
patients aged ≥75 years. The large projected increase in AF prevalence associated with temporal changes in AF-related
comorbidities suggests the need for comprehensive implementation of AF prevention and management strategies. ( J Am Heart
Assoc. 2017;6:e005155. DOI: 10.1161/JAHA.116.005155.)
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T he lifetime risk of developing atrial ﬁbrillation (AF)among those aged ≥40 years is 1 in 4.1,2 The
incidence of AF increases dramatically with age and is higher
in men than women.1,2 Although incidence and prevalence
rates vary from country to country, virtually every reported
study has demonstrated an increased incidence and preva-
lence, which is projected to rise substantially in the ensuing
decades.1–7 The majority of these observations have included
AF patients as part of cohort studies or AF registries. There
are scant data reﬂecting unselected clinical populations, such
as those seen in general practice.
Recent estimates suggest that 12.1 to 15.9 million
patients will have AF in the United States by 20506 and
17.9 million people in Europe by 2060.3,5 Given the increased
risk of stroke, morbidity, and death related to AF, these
increases in prevalence will have a considerable public health
burden. A recent analysis of the Framingham cohort demon-
strated a 3- to 4-fold rise in age-adjusted incidence between
1958 and 1967 and 1998 and 2007, with temporal changes
in AF-associated risk factors, such as increases in the
prevalence of diabetes mellitus and obesity, despite
decreases in heart failure, heavy alcohol intake, and smok-
ing.8 Increased AF awareness and initiatives to improve
detection of AF9–11 have contributed to the greater incidence
and reported prevalence of AF, in addition to an aging
population and improved survival from other cardiovascular
diseases. The greater impetus to detect and treat AF has been
advocated in clinical guidelines.12–15 In the UK, AF has been
From the University of Birmingham Institute of Cardiovascular Sciences, City
Hospital, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham,
United Kingdom (D.A.L., G.Y.H.L., D.K.); Aalborg Thrombosis Research Unit,
Department of Clinical Medicine, Aalborg University, Aalborg, Denmark (D.A.L.,
G.Y.H.L., T.B.L.); Department of Cardiology (F.S., T.B.L.) and Unit of Clinical
Biostatistics and Bioinformatics (F.S.), Aalborg University Hospital, Aalborg,
Denmark; Monash University Center of Cardiovascular Research and Education,
Melbourne, Australia (D.K.).
*Dr Lane and Dr Skjøth are joint ﬁrst authors.
†Dr Lip and Dr Kotecha are joint senior authors.
Correspondence to: Deirdre A. Lane, PhD, University of Birmingham Institute
of Cardiovascular Sciences, City Hospital, Sandwell and West Birmingham
Hospitals NHS Trust, Dudley Rd, Birmingham B18 7QH, United Kingdom.
E-mail: deirdrelane@nhs.net
Received November 29, 2016; accepted January 25, 2017.
ª 2017 The Authors. Published on behalf of the American Heart Association,
Inc., by Wiley. This is an open access article under the terms of the Creative
Commons Attribution-NonCommercial-NoDerivs License, which permits use
and distribution in any medium, provided the original work is properly cited,
the use is non-commercial and no modiﬁcations or adaptations are made.
DOI: 10.1161/JAHA.116.005155 Journal of the American Heart Association 1
ORIGINAL RESEARCH
 by guest on M
ay 2, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
added to the Quality Outcomes Framework, where appropri-
ate identiﬁcation and management of AF in primary care is
rewarded and incentivized.
The purpose of the present analysis was to investigate
temporal trends in AF incidence, comorbidities, and mortality
in a primary care population representative of contemporary
clinical practice. Our aim was to gain insight into the future AF
population proﬁle and make projections of the likely change in
AF prevalence to 2060, in the UK.
Methods
Data Source
Data for this study were obtained from the UK Clinical
Practice Research Datalink (CPRD), a primary care database
(GOLD) linked to the Hospital Episode Statistics (HES) and
the Ofﬁce for National Statistics (ONS). The CPRD GOLD
contains the computerized medical records from represen-
tative primary care practices in the UK, currently providing
care to 8% of the UK population. All patients in the UK
are registered with a general practitioner (GP). Information
comprising patient demography, medical history, medica-
tions, hospitalizations, specialist referrals, and clinical
events are captured electronically.16 The CPRD validates
the data quality from each practice primarily from death
records and gaps in data transfer, and analyses are only
performed on data for periods where the practices are
considered to deliver data “up-to-standard.” Systematic
reviews of the medical diagnoses in the database, including
AF, have demonstrated high overall validity,17,18 with a
median positive predictive value of 89%.17 All admissions to
National Health Service (NHS) hospitals in England are
captured by the HES, which records the date of admission
and discharge and the main diagnoses, with data available
from 1997 onward. UK population data and projections
were extracted from reference tables available from the
ONS (www.ons.gov.uk). Ethics approval for the study was
not required because these were secondary analyses of
anonymized data.
Study Population
The study population comprised adults aged ≥18 years with
a ﬁrst (incident) diagnosis of AF either based on read codes
identiﬁed by the CPRD or on hospital discharge code
(International Classiﬁcation of Diseases, Tenth Revision
[ICD-10]: I48) or both. Patients with any type of valvular
heart disease or past valve interventions were excluded.
The inclusion period was from January 1, 1998 to
December 31, 2010 to ensure availability of corresponding
HES data.
The presence of comorbid conditions were recorded, includ-
ing hypertension, diabetes mellitus, ischemic heart disease,
cerebrovascular disease, heart failure (clinical diagnosis) vas-
cular disease, and renal disease, as deﬁned by their corre-
sponding Read code or ICD-10 code, either preceding or during
the same visit as the incident AF diagnosis. Individual baseline
CHA2DS2-VASc scores were calculated to assess stroke risk.
19
The CHA2DS2-VASc score assigns 2 points each for age
≥75 years and previous stroke or transient ischemic attack
(TIA) and 1 point each for the presence of congestive heart
failure, hypertension, diabetesmellitus, vascular disease, age 65
to 74 years, and female sex (scores range from0 to 9). Only year
of birth is provided by the CPRD; therefore, date of birth was
assumed as June 15 for age calculation. Prescribed medications
at AF diagnosis, including oral anticoagulation (OAC) and
cardiovascular medications, were also recorded. A prescription
within 3 months preceding AF diagnosis was assumed as an
indication for active treatment at the date of AF diagnosis.
Statistical Analysis
Baseline demographic and clinical characteristics of the
incident AF population are presented as number and
percentage, mean (SD), or median (interquartile range), as
appropriate. We prespeciﬁed 3 time periods (1998–2001,
2002–2006, and 2007–2010). Age-adjusted incidence rates
were calculated as weighted averages on crude rates for each
age, with weights given as proportions of persons with the
corresponding age in the UK population. CIs were calculated
according to Fay and Feuer.20 Age-adjusted incidence rates
are reported at the population level and for 5 age groups (<55,
55–64, 65–74, 75–84, and ≥85 years). Data on those aged
18 to 54 years were combined because of small numbers.
Effect of age on incidence is represented by a natural cubic
spline and estimated by Poisson regression on the number of
AF events on age and the year of diagnosis, with the natural
logarithm of person time at risk as offset. The person time at
risk per year and age group in each center was provided by
the CPRD and was subsequently scaled to the UK proportion
in each year. Trend over years was tested by estimating the
linear effect of year, complemented by a likelihood ratio test
for reducing from a factorial to linear effect of year.
The projection of the prevalence of AF, pij, at age level i in
year j was calculated iteratively based on age level incidence ri
and mortality Mi as
pij¼
ðpi1;j1þð1pi1;j1Þ  r i  ð1þqÞjÞ  ð1ð1MiÞRRAFÞ
1Mi
with the overall relative mortality of AF patients, RRAF,
assumed to be constant across all ages. This is a slightly
modiﬁed version of the formula presented by Miyasaka et al.6
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An annual constant increase in incidence may be given by
q>0, also implying equal relative increase across age groups.
Incidence was estimated as described above, whereas
mortality rates were extracted from the UK population
statistics provided by the ONS in 2010. An excess mortality
for AF compared to non-AF patients of 50% was assumed, that
is, RRAF=1.5. This value was chosen as a conservative
representation of previously published data. We also per-
formed a range of sensitivity analyses (including mortality
excesses of 20% and 100% and a more-detailed age-
dependent mortality model based on the comparison of
observed and expected deaths according to ONS statistics).
Prevalence in 2010 was estimated directly from the CPRD
cohort and used as a basis for the projection of prevalence
from 2011 to 2060 on the assumption of a constant incidence
(q=0), as well as with an assumed 1% annual increase in
incidence (q=0.01). Using ONS projections of the UK
population size, NUK,ij, at age group i in year j, the expected
number of AF patients at year j was obtained as
NAF;j ¼
X
i
pij  NUK;ij
and the overall prevalence pj=NAF,j/∑iNUK,ij.
AF-related mortality was described in terms of number of
deaths divided by the total person time at risk 1 year after the
date of diagnosis. Person time was censored at the time of
transfer out of clinic, the last data transfer from the clinic, or
end of study (December 31, 2010). The trend for crude
mortality across the time period studied in patients with
3 years of follow-up was calculated using an incidence rate
ratio (IRR) based on Poisson regression.
All statistical analyses were performed using Stata soft-
ware (version 13.1; StataCorp LP, College Station, TX).
Results
Population and Comorbidities
A total of 57 818 patients were identiﬁed with incident AF
between January 1, 1998 and December 31, 2010. This
included 27 943 women (48.3%) with a mean age of 77.2 (SD,
10.7) and 29 875 men (51.7%) with a mean age of 71.5 (12.0)
years. Table 1 presents the baseline characteristics of the
cohort overall and by time period (1998–2001, 2002–2006,
and 2007–2010). There was clear evidence of an ageing AF
population, with the proportion of over 85-year-olds increas-
ing from 15.5% in 1998–2001 to 19.0% in 2007–2010.
Prevalence of associated comorbidities at the time of AF
diagnosis varied over time (Table 1). The proportions of AF
patients with a previous stroke/TIA and vascular disease
remained fairly constant (11–15%), whereas clear increases
were observed in the prevalence of hypertension and diabetes
mellitus (46–61% and 9–14%, respectively). Ischemic heart
disease at the time of AF diagnosis decreased (44–37%).
Although we noted a decrease in the number of incident AF
patients with a clinical diagnosis of heart failure (17–10%), the
adoption of more-stringent diagnostic criteria during the study
period was a confounding factor. Overall, the CHA2DS2-VASc
score remained similar across all time periods (mean, 3.2; SD,
1.9). Type of AF was not consistently reported.
Medications at the time of incident AF diagnosis are
displayed in Table 1. Anticoagulation pre-existing the diagno-
sis of AF was uncommon (n=2709; 4.7%). There was a steady
increase in use of angiotensin-converting enzyme (ACE)
inhibitors and beta-blockers from 1998 to 2010 and a steep
decline in the use of digoxin.
Incidence of AF
The incidence of AF increased with age from 0.13 per
1000 person-years in those aged <55 years to 7.65 per
1000 person-years in those aged ≥85 years (Table 2). Inci-
dent AF was greater in men compared to women (1.33 vs
1.18 per 1000 person-years, respectively).
Comparing the 3 time periods, the overall age-adjusted
incidence rate of AF per 1000 person-years was 1.11 in
1998–2001 (95% CI, 1.09–1.13), 1.33 in 2002–2006 (1.31–
1.34), and 1.33 in 2007–2010 (1.31–1.35; Table 2). Although
incidence rates were fairly static for younger patients, they
continued to increase in older patients, both in women and
men (Figure 1).
Mortality in Patients With Incident AF
Averaged over all time periods, the crude 1-year mortality rate
was 8.8% in women with incident AF (95% CI, 8.4–9.1%) and
10.6% in men (95% CI, 10.2–11.0%). As expected, older
patients had substantially higher mortality: 1.0% (18–
39 years), 2.2% (40–54 years), 3.2% (55–64 years), 6.0%
(65–74 years), 10.4% (75–84 years), and 23.7% (≥85 years)
per year.
Two age groups were modeled to assess mortality over
time (Figure 2). In patients aged 55 to 74 there was a
reduction in mortality (IRR per calendar year, 0.97; 95% CI,
0.95–0.99; P<0.001). In contrast, patients aged ≥75 years
had similar mortality between 1998 and 2010 (IRR, 1.00; 95%
CI, 0.99–1.01; P=0.84).
Sensitivity analyses for mortality all identiﬁed similar and
consistent results (data not shown).
Projected Prevalence of AF
Based on the study population, the number of AF patients in the
UK in 2010 is estimated at 718 334 adults (corresponding to an
overall prevalence of 14.5 per 1000 and 83.6 per 1000 among
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the population aged 75 and above). Using the prevalence model
described and assuming a constant incidence rate from 2010
onward, the projected number of adults with AF in the UK will be
1 085 078 by 2040 and 1 258 705 by 2060. With a constant
1% increase in the incidence rate, the projected number of AF
patient is 1 322 694 by 2040 and 1 846 960 by 2060.
Prevalence rates are projected to rise faster in men than women
(Table 3). Overall, the burden of AF as a proportion of the
population is projected to dramatically increase year on year
(Figure 3).
Discussion
Using a general practice database linked to hospital records
and national epidemiological data, our principal ﬁndings show
an increase in the overall age-adjusted incidence of AF
between 1998 and 2001 and 2002 and 2006 (from 1.11 to
1.33 per 1000, respectively), followed by a plateau between
2007 and 2010; however, the incidence continued to rise in
those patients over the age of 75 years, both in women and
men. Second, mortality in these older patients has not
decreased in line with younger patients with incident AF,
despite apparent improvements in management, both phar-
macological and interventional. Third, the projected preva-
lence of AF based on our data will dramatically increase and
pose a considerable public health burden, and even assuming
no increase in the incident AF rate, this will still equate to
almost 1.3 million patients with AF by 2060 in the UK alone.
Accounting for the increasing incidence of AF, this ﬁgure
could rise to over 1.8 million patients.
A number of studies have explored the incidence of AF,
including the Netherlands,1 Germany,21 Iceland,7 and the
United States.4,6,8,22–24 A global systematic review reported a
signiﬁcant rise in the incidence of AF between 1990 and
2010. The incidence of AF in 2010 was 59.5 per 100 000
population (95% uncertainty interval [UI], 49.9–74.9) in
women and 77.5 (95% UI 65.2–95.4) in men, an increase of
35% for women and 28% for men from 1990.3 All of these
Table 1. Baseline Demographic and Clinical Characteristics of Incident AF
Baseline Characteristic Overall, n (%) 1998–2001, n (%) 2002–2006, n (%) 2007–2010, n (%)
No. of patients 57 818 12 035 24 824 20 959
Age, y, mean (SD) 74.2 (11.7) 74.0 (11.6) 74.1 (11.8) 75.0 (11.8)
Age group, y
18 to 40 650 (1.1) 155 (1.3) 287 (1.2) 208 (1.0)
41 to 54 3156 (5.5) 656 (5.5) 1376 (5.5) 1124 (5.4)
55 to 64 7697 (13.3) 1507 (12.5) 3311 (13.3) 2879 (13.7)
65 to 74 15 483 (26.8) 3414 (28.4) 6641 (26.8) 5428 (25.9)
75 to 84 20 990 (36.3) 4442 (36.9) 9214 (37.1) 7334 (35.0)
≥85 9842 (17.0) 1861 (15.5) 3995 (16.1) 3986 (19.0)
Women 27 943 (48.3) 5882 (48.9) 12 146 (48.9) 9915 (47.3)
Previous stroke or TIA 8440 (14.6) 1805 (15.0) 3559 (14.3) 3076 (14.7)
Ischemic stroke 6464 (11.2) 1499 (12.5) 2619 (10.6) 2346 (11.2)
Hypertension 31 962 (55.3) 5540 (46.0) 13 645 (55.0) 12 777 (61.0
Diabetes mellitus 6595 (11.4) 1014 (8.4) 2743 (11.0) 2838 (13.5)
Heart failure* 7372 (12.8) 2099 (17.4) 3261 (13.1) 2012 (9.6)
Ischemic heart disease 23 242 (40.2) 5309 (44.1) 10 120 (40.8) 7813 (37.3)
Vascular disease 8162 (14.1) 1760 (14.6) 3464 (14.0) 2938 (14.0)
Peripheral arterial disease 1880 (3.3) 420 (3.5) 768 (3.1) 692 (3.3)
Mean (SD) CHA2DS2-VASc score 3.2 (1.9) 3.1 (1.9) 3.2 (1.9) 3.0 (1.9)
ACE inhibitor† 14 141 (24.5) 2114 (17.6) 5880 (23.7) 6147 (29.3)
Beta-blockers† 13 592 (23.5) 2159 (17.9) 6042 (24.3) 5391 (25.7)
Digoxin† 3839 (6.6) 1468 (12.2) 1762 (7.1) 609 (2.9)
ACE indicates angiotensin-converting enzyme; TIA, transient ischemic attack.
*A change in the Quality Outcomes Framework (QOF) deﬁnition of heart failure between 2002–2006 and 2007–2010 means that heart failure diagnosis is not directly comparable across
the 3 time points.
†A prescription within 3 months before atrial ﬁbrillation (AF) diagnosis was assumed as an indication for active treatment on the date of AF diagnosis.
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cohorts differ markedly in their patient population, including
hospitalized patients,7 administrative databases,6,24 health
insurance cohorts,4,21,23 and population-based prospective
cohorts.1,8 Five previous studies6–8,22,25 have examined the
incidence of AF at multiple time points, whereas others have
taken a “snapshot” of the overall incidence of AF and by sex
Table 2. Age-Adjusted Incidence Rates (With 95% Conﬁdence Intervals) of AF in the UK Overall and by Sex, Stratiﬁed by Calendar-
Year of Diagnosis
Age-Adjusted Incidence
Per 1000 (95% CI) Overall 1998–2001 2002–2006 2007–2010
All patients; overall, y 1.26 (1.25–1.27) 1.11 (1.09–1.13) 1.33 (1.31–1.34) 1.33 (1.31–1.35)
<55 0.13 (0.13–0.13) 0.12 (0.11–0.13) 0.14 (0.13–0.15) 0.13 (0.13–0.14)
55 to 64 1.16 (1.13–1.19) 1.06 (1.00–1.12) 1.20 (1.16–1.24) 1.22 (1.17–1.26)
65 to 74 3.24 (3.19–3.30) 3.02 (2.92–3.13) 3.42 (3.34–3.50) 3.26 (3.18–3.35)
75 to 84 6.42 (6.33–6.52) 5.72 (5.55–5.89) 6.84 (6.71–6.99) 6.66 (6.51–6.82)
≥85 7.65 (7.48–7.81) 6.27 (5.98–6.58) 8.05 (7.80–8.31) 8.73 (8.46–9.01)
Men; all ages, y 1.33 (1.32–1.35) 1.17 (1.14–1.20) 1.39 (1.37–1.42) 1.43 (1.41–1.46)
<55 0.19 (0.18–0.19) 0.17 (0.15–0.18) 0.20 (0.19–0.21) 0.19 (0.18–0.20)
55 to 64 1.55 (1.51–1.60) 1.43 (1.34–1.53) 1.60 (1.53–1.67) 1.62 (1.55–1.70)
65 to 74 3.97 (3.89–4.06) 3.78 (3.62–3.96) 4.06 (3.94–4.20) 4.05 (3.91–4.20)
75 to 84 7.12 (6.98–7.28) 6.34 (6.06–6.64) 7.54 (7.32–7.78) 7.45 (7.20–7.70)
≥85 8.24 (7.93–8.56) 6.65 (6.08–7.26) 8.69 (8.21–9.19) 9.57 (9.06–10.09)
Women; all ages, y 1.18 (1.16–1.19) 1.05 (1.02–1.08) 1.26 (1.24–1.28) 1.22 (1.20–1.25)
<55 0.07 (0.07–0.07) 0.06 (0.06–0.07) 0.07 (0.07–0.08) 0.07 (0.06–0.08)
55 to 64 0.76 (0.73–0.80) 0.68 (0.62–0.74) 0.80 (0.75–0.85) 0.81 (0.76–0.87)
65 to 74 2.58 (2.51–2.64) 2.35 (2.22–2.48) 2.82 (2.72–2.93) 2.53 (2.42–2.64)
75 to 84 5.93 (5.81–6.04) 5.30 (5.09–5.52) 6.35 (6.18–6.53) 6.08 (5.89–6.27)
≥85 7.37 (7.18–7.57) 6.11 (5.77–6.47) 7.77 (7.48–8.07) 8.33 (8.01–8.66)
AF indicates atrial ﬁbrillation.
75-84
0 2 4 6 8 10
1998-
2001
2002-
2006
2007-
2010
55-64
65-74
18-54
≥85
75-84
55-64
65-74
18-54
≥85
75-84
55-64
65-74
18-54
≥85
0.8
1.0
1.2
1.4
1.6
1.8
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MenWomen
1000 by age-group and year of diagnosis 1000 by gender and year of diagnosis
A B
Figure 1. Age-adjusted annual incidence rate of atrial ﬁbrillation per 1000 in the UK (1998–2010)
showing (A) increases in incidence over time with increasing age, particularly in older patients, and (B) sex-
stratiﬁed incidence of atrial ﬁbrillation with higher rates in men.
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and age group at 1 particular period of time.1,4,23,26,27 All
studies, with the exception of 1,24 demonstrate an increase in
the overall incidence of AF over time, with increasing age, and
a greater incidence in men than women.1,6–8,21–23,25–27
CPRD data linkage with hospital records and national
epidemiological data provides us with a unique opportunity to
assess incidence rates and comorbidity patterns in a sample
of patients’ representative of general practice in a developed
country (the UK). Several studies have validated CPRD data
and conﬁrmed the data quality and completeness of the
clinical records.17,18,25,28 Comparison with both the Framing-
ham8 and Olmsted County6 cohorts in the United States
suggest that incident AF is much lower in our UK primary care
cohort. The 2 US Medicare beneﬁciary databases of people
aged ≥65 years report higher incident rates of AF per
1000 person-years22,23 than are evident in a similar German
population21 and other European cohorts.1,7 Some variation in
incident AF rates may be attributed to the heterogeneity and
source of the cohorts, diverse follow-up periods, and different
deﬁnitions of incident AF.
Three previous analyses have been conducted using
general practice data. Analysis of CPRD data captured
between 1993 and 2005 show a temporal increase in
incident AF, with a similar pattern over time by age group
and sex to our ﬁndings.27 In a Scottish primary care cohort
examining the incidence of AF in men and women in 2001–
2002, analogous rates of incident AF were demonstrated
compared to our cohort.26 In a more-recent UK analysis,
identiﬁcation of AF and initiation of anticoagulant therapy
was observed to improve over a 12-year period.25 Although
this is important for the prevention of stroke and throm-
boembolism, our ﬁnding of no substantial change in
mortality from 1998 to 2010 in patients aged 75 years
and older is an important reminder that death in AF
patients is typically a consequence of sudden death or
progressive heart failure.29,30 Thus, additional attention is
warranted to impact on the static, high death rates
observed in older AF patients. Indeed, a recent analysis
of Olmstead County residents revealed no change in
survival between 2000 and 2010 among those AF patients
who survived the ﬁrst 90 days after AF diagnosis (hazard
ratio [HR], 1.05; 95% CI, 0.85–1.31).24
We also observed changes in the comorbidity patterns of
patients with incident AF across the 12 years of our study.
Whereas some are linked to an ageing population, others
require further consideration of their impact on clinical
management. For example, the increase in diabetes mellitus
and hypertension we identiﬁed were out of proportion with
the increase in age, probably reﬂecting better diagnosis or
changes in prevalence. Obesity, diabetes mellitus, and the risk
of AF are closely related, and diabetes mellitus is both an
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Figure 2. One-year crude mortality rates and 95% CIs according
to the year of incident atrial ﬁbrillation. In patients aged 55 to
74 years, there was a signiﬁcant reduction over time (incidence
rate ratio per calendar year, 0.97; 95% CI, 0.95–0.99; P<0.001),
whereas no difference in mortality was observed in patients aged
≥75 years (incidence rate ratio, 1.00; 95% CI, 0.99–1.01;
P=0.84).
Table 3. Projected Prevalence of AF Per 1000 Persons
Model
Projected Prevalence (Per 1000)
Age-Dependent Mortality
Constant Incidence
Constant Excess Mortality
Increased Incidence
Year Overall Females Males Overall Females Males
2010 14.5 12.9 16.3 14.5 12.9 16.3
2020 15.5 13.8 17.2 15.5 13.5 17.7
2040 20.5 18.7 22.3 23.1 20.4 25.8
2060 25.4 23.9 26.9 32.0 29.0 34.9
AF indicates atrial ﬁbrillation.
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Figure 3. Estimated change from 2010 in the UK population
and numbers of patients with AF in comparison to the predicted
United Kingdom population, assuming increased incidence of AF.
AF indicates atrial ﬁbrillation.
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independent risk factor for incident AF and associated with
stroke in AF patients.31,32 We also saw unexpected decreases
in the rate of heart failure in patients diagnosed with incident
AF, similar to that observed in the Framingham cohort.8 This
may represent earlier diagnosis of AF, before the onset of
heart failure, or more-stringent diagnostic deﬁnitions. Indeed,
AF and heart failure are closely linked in pathophysiology and
the combination is associated with high levels of morbidity
and mortality,33 regardless of ejection fraction.34 Earlier
diagnosis of AF and the prevention of heart failure are
important treatment goals that may lead to an improvement in
prognosis. The temporal decrease we observed in ischemic
heart disease is compatible with UK national statistics for the
general population.35 The rates of OAC prescription reported
here are very low because the data reﬂect the proportion of
patients receiving this medication at the time of AF diagnosis
and in the 3 months beforehand, not after AF diagnosis.
With regard to the future prevalence of AF, 4 studies
have reported a dramatic increase in projected AF.4,6,7,36
Data from the most recent retrospective health insurance
claim database estimated that 1.8 million US citizens would
be newly diagnosed with AF by 2030 without any increase
in incident AF.4 However, a logarithmic progression in AF
incidence would result in 2.6 million new cases by 2030,
translating into a prevalence of 12.3 million,4 similar to
projections made from the Olmsted County cohort.6 In an
Icelandic study, the projected prevalence of AF in 2030 will
be 2.9% (95% CI, 2.8–2.9; assuming constant incidence and
mortality rates), rising to 3.8% in 2050 or 4.3% if incidence
and mortality rates increase.7 Our data conﬁrm that the UK
will also see substantial increases in AF prevalence relative
to population growth and highlights the enormous potential
impact this will have on health care provision and
expenditure. Attributed to increased AF awareness and
more-intensive monitoring (eg, implantable devices and
smartphone applications), the detection of AF is also
improving rapidly.10,37,38 The costs of care associated with
AF are high and continue to increase, adding to the global
health care burden of AF.39,40
Strengths and Limitations
The strength of our analysis was the use of one of the
largest unselected population cohorts of patients with
incident AF, using a well-validated general practice database
with linkage to hospital records. The sample size allowed us
to investigate differences in incidence, comorbidities, and
mortality across a 12-year period in a contemporary
population and project prevalence of AF with a high degree
of conﬁdence. As with any data linkage study, we are
reliant on accurate coding of diagnoses and have limited
capability to interrogate any discrepancy in diagnosis, type
of AF, comorbidities, or prescribing data. Nevertheless,
CPRD has demonstrated excellent levels of external valid-
ity.17 Although we had no electrocardiogram data to
corroborate the AF diagnosis, a previous validation study
of diagnostic coding for AF in CPRD (undertaken by
manually reviewing computerized patient records and
externally conﬁrmed by a questionnaire to the GP) has
shown that the recording of AF in primary care is
consistent and valid, with a positive predictive value of
98%.41 In addition, we were able to conﬁrm diagnoses of
AF made in the hospital by linkage to the HES. Although
the general practices that supply data to CPRD are self-
selected, they appear to be representative of the general
UK population. Data on ethnicity were missing for 19.7%,
and therefore the impact of ethnicity on incidence and
prevalence could not be examined. Given that ethnicity has
been shown to inﬂuence AF incidence in other studies, this
may impact future incidence and prevalence estimates.
Finally, awareness of AF has the potential to impact on
incidence in a nonlinear way that would not be accounted
for in our incidence and prevalence projections. Conversely,
patients with asymptomatic AF may be less likely to come
to the attention of their general practitioner, and hence our
estimates on incidence and prevalence could be underes-
timates of the true burden of AF in the community.
Conclusions
In a large general practice population, incident AF increased
and then plateaued overall, with a continued increase in
patients aged ≥75 years and was more common in men than
women. Projections suggest that between 1.3 and 1.8 million
people in the UK will have AF by 2060, constituting a
considerable public health burden. The large projected
increase in AF prevalence associated with temporal changes
in AF-related comorbidities (particularly, hypertension and
diabetes mellitus) suggests the need for comprehensive
implementation of AF prevention and management strategies.
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